[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,808,006
  • Shares Outstanding, K 153,084
  • Annual Sales, $ 616,290 K
  • Annual Income, $ 447,180 K
  • EBIT $ 150 M
  • EBITDA $ 147 M
  • 60-Month Beta 1.68
  • Price/Sales 9.64
  • Price/Cash Flow 13.85
  • Price/Book 10.19

Options Overview Details

View History
  • Implied Volatility 44.60% (+0.65%)
  • Historical Volatility 58.74%
  • IV Percentile 7%
  • IV Rank 5.52%
  • IV High 111.36% on 07/10/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 19) 3.20 (8.42%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 977
  • Volume Avg (30-Day) 3,951
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 57,577
  • Open Int (30-Day) 68,947
  • Expected Range 34.74 to 41.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.38
  • Number of Estimates 5
  • High Estimate $0.59
  • Low Estimate $0.11
  • Prior Year $0.17
  • Growth Rate Est. (year over year) +123.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.23 +14.17%
on 05/01/26
44.65 -15.03%
on 05/08/26
+4.36 (+12.98%)
since 04/29/26
3-Month
26.76 +41.78%
on 03/12/26
44.65 -15.03%
on 05/08/26
+7.85 (+26.09%)
since 02/27/26
52-Week
25.28 +50.08%
on 08/11/25
44.65 -15.03%
on 05/08/26
+2.80 (+7.97%)
since 05/28/25

Most Recent Stories

More News
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies...

TGTX : 37.94 (-2.27%)
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only ...

TGTX : 37.94 (-2.27%)
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy) data in adults with...

TGTX : 37.94 (-2.27%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 37.94 (-2.27%)
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately...

TGTX : 37.94 (-2.27%)
TG Therapeutics Reports Tuesday With Analysts Already Backing Away From Their Own Estimates

Barchart Research What to Expect from TGTX Earnings TGTX Generated May 5, 2026 Current Price $36.10 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Reports Tuesday...

TGTX : 37.94 (-2.27%)
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association...

TGTX : 37.94 (-2.27%)
DTIL : 6.97 (+0.72%)
TG Therapeutics Consensus Appears Stale After Recent Downgrades—But Visibility Remains Low

Barchart Research What to Expect from TGTX Earnings TGTX Generated May 1, 2026 Current Price $33.85 EPS Estimate $$0.23 Consensus Rating Moderate Buy Average Move 12.28% TG Therapeutics Consensus Appears...

TGTX : 37.94 (-2.27%)
TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the...

TGTX : 37.94 (-2.27%)
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms...

TGTX : 37.94 (-2.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 40.32
2nd Resistance Point 39.81
1st Resistance Point 38.87
Last Price 37.94
1st Support Level 37.42
2nd Support Level 36.91
3rd Support Level 35.97

See More

52-Week High 44.65
Last Price 37.94
Fibonacci 61.8% 37.25
Fibonacci 50% 34.97
Fibonacci 38.2% 32.68
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.